The Vav protooncogene is expressed almost exclusively in hematopoietic cells, but its role in regulating adult human hematopoietic cell development remains uncertain. To analyze Vav function in adult blood cell formation, we used antisense (AS) oligodeoxynucleotides (ODN) t o disrupt its expression in normal and malignant human hematopoietic cells. Bone marrow or peripheral blood mononuclear cells (MNC) were obtained from consenting normal donors and patients with acute or chronic myelogenous leukemia (AML and CML, respectively) and polycythemia vera (PV). Adherent and T-cell-depleted (A-T-) MNC or CD34+ MNC were exposed t o unmodified sense, antisense, or scrambled sequence ODN corresponding t o codons 2-7 of Vav's mRNA sequence. Cells were then assayed for Vav mRNA expression by reverse transcription-polymerase chain reaction and Vav protein expression by Western blotting. After showing that Vav-targeted AS ODN could specifically diminish Vav mRNA and protein expression, we assessed the ability of Vav-deficient cells t o form myeloid and erythroid colonies in methylcellulose cultures. When normal CD34+ MNC were exposed HE VAV ONCOGENE was discovered by Katzav et all while screening esophageal carcinomas for transforming oncogenes. Its normal cellular counterpart, the vav protooncogene (proto-Vav), was subsequently cloned from a tumor cell cDNA library using a fragment of the transforming gene as a probe. Initial sequence analysis of Vav predicted that the encoded protein would be functionally complex and this has since been verified."' At its amino terminus, Vav has been shown to contain helix-loop-helix (HLH)-and leucine zipper (LZ)-like motifs (Fig  1 ) , suggesting possible transcriptional control functions.'" Of interest, deletion of the HLH domain creates a protein with the ability to transform cells, as occurs in the vav oncogene.' Adjacent to the HLH and LZ domains is a region with pleckstrin homologyX and homology to the human dhl oncogene, the bcr gene, Cdc 25, and the yeast CDC24 gene.'."' All of these genes encode proteins with the potential to function as guanine nucleotide exchange factors (GEFs) Hemutology. 0006-4971/96/8704-0044$3.00/0 1326 t o Vav AS ODN, no effect on colony-forming unit-granulocyte-macrophage (CFU-GM) or CFU-megakaryocyte colony formation was observed. In contrast, erythroid colony growth was inhibited by a mean f SD of 6296 f 16%. In patients with hematopoietic malignancies, Vav-targeted AS ODN inhibited CFU-GM colony formation in a sequence-specific and dose-dependent manner in 1 of 3 AML, 13 of 17 CML, and 2 of 2 PV patients. At the highest concentration used, the Vav AS ODN inhibited CFU-GM colony formation from 66% t o 81% when compared with control cell colony growth. Burst-forming unit-erythroid (BFU-E) colony formation was also assessed in 7 PV patients. The Vav-targeted AS ODN inhibited BFU-E colony formation in all by a mean f SD of 81% f 4%. These findings suggest that Vav function may not be easily complemented in a significant subset of normal adult erythroid progenitor cells and may also be necessary for myeloid progenitor cell growth in a variety of hematopoietic malignancies.
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molecule. ' The presence of a pleckstrin homology (pH) domain adjacent to the putative GEF domain further suggests that interaction with as yet unidentified protein(s) or lipids may be necessary for GEF activity and recent studies from our group support this concept.'" Following downstream of the GEF domain is a cysteine-rich (CR) region that appears similar to the phorbol ester binding domain of protein kinase C.' The CR is flanked by two nuclear translocation (NTr) signal motifs, further suggesting that Vav may play some role in regulating gene expression.' Although doubts have been raised about the functionality of the NTr motifs,"." studies from our lab showing that Vav rapidly undergoes nuclear translocation in prolactin stimulated Nb2 cells"' and that the protein can interact with heterogeneous ribonucleoprotein K'"." imply that Vav effects on gene expression at the transcriptional or posttranscriptional level may yet be identified. Finally, it has also been shown that, at its carboxy terminus, Vav contains a src homology 2 (SH2) domain flanked by two src homology 3 (SH3) domains.Is
The coexistence of an SH2 domains and guanine nucleotide exchange factor motifs in the same molecule suggests that Vav may function as a GTP-GDP exchange factor for Ras family proteins during receptor-mediated signaling. A number of observations support this hypothesis. For example, we have recently shown that Vav associates directly with the prolactin receptor, a member of the growth factor receptor supergene family."' It has also been shown that Vav phosphorylation occurs on tyrosine in its SH2 domain.".'" In addition, when NIH3T3 cells in which Vav is overexpressed are stimulated by epidermal growth factor (EGF) and platelet-derived growth factor (PDGF), Vav's level of tyrosine phosphorylation is increased."." Perhaps more germane to this report, recent studies in human hematopoietic cell lines show that Vav is rapidly phosphorylated when cells are exposed to interleukin-3 (IL-3), granulocyte-macrophage 
MATERIALS AND METHODS
Cdl.s. K T -mononuclear cells (MNC) and CD34' cells were obtained l'rom normal marrow tionors as previously dcscribed.2","' Malignant A MNC or A~ T ~ MNC wcrc isolated from the bone marrow or peripheral blood of patients with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), or polycythemia vera (PV) using the m n c tcchniques. 0 3 4 ' cells were isolated with a Cepratc LC (CD34) laboratory cell scpxation system (CellPro Inc, Bothell, WA) according to the manufacturer's directions.
Oli~ Westrnt blotting. Vav protein analysis was performed by Westem blotting. as previously described,"' using cells that had been exposed to ODN as described above. After transfer to nitrocellulose, the membrane was probed for Vav protein with an anti-Vav antibody (Santa Cruz Biotechnology, Santa Cruz. CA). Proimmune or isotypematched antibody served as controls. Antigen-antibody complexes were then detected using enhanced chemiluminescence (ECL kit: Amersham, Arlington Heights. IL).
Srotisriccd crnn/wis. Statistical significance of experimental results was determined using the Student's t-test for unpaired samples.
Statistical significance was inferred if calculated P < .05.
RESULTS

Efect sf Vav ODN cm Vav mRNA and protein expression.
For reasons relating to mRNA half-life, secondary structure, amciated proteins, and other poorly defined factors governing target sequence accessibility, not every mRNA species is easily inhibited using an antisense approach. We therefore sought to determine if Vav mRNA expression could be perturbed in hematopoietic cells using antisense ODN (Fig 2) . Marrow MNC were isolated from normal donors and then placed in suspension culture untreated, or in the presence of ODN. Thirty-six hours after initiation of the cultures, cells were analyzed (Fig 2, lane  A, top panel) . Simultaneous assay for &actin mRNA showed detectable message regardless of the Vav ODN sequence to which cells were exposed (Fig 2, bottom panel) . Similar results were obtained when CML or PV cells were exposed to Vav ODN. Accordingly, Vav mRNA appeared to represent a feasible antisense ODN target.
Determination of Vav requirements for normal human hematopoietic progenitor cell growth. To assess the functional role of Vav in normal adult hematopoietic cell development. we exposed CD34' MNC cells to Vav ODN and then examined effects on subsequent burst-forming unit-erythroid (BFU-E), CFU-GM, CFU-Meg, and CFU-Mix colony formation ( Table 1) . For screening purposes, we used an ODN concentration of 150 p,g/mL because we had already determined (Fig 2) that exposing MNC to this dose of ODN extinguished, at least transiently, Vav ODN mRNA expression. When MNC were incubated in the Vav ODN at this concentration, no discernible effect on CFU-GM-or CFUMeg-derived colony formation was observed. In contrast, BFU-E and CFU-Mix colonies were inhibited by 73% and liferation or maturation. Accordingly, it is possible that CFUMix colony inhibition results from disrupted erythroid cell development rather than from direct perturbation of the CFU-Mix progenitor's growth. At present, these possibilities are not easy to distinguish. The overall results suggest that the erythroid lineage is most dependent on Vav function, at least at the level of maturation studied in the culture system used. Finally, inhibition of BFU-E-derived colonies was found to be dose-dependent and sequence-specific because neither S nor Scr sequences had any significant effect on colonies formed (Fig 3) .
Effect of pulse ODN exposure on Vav mRNA expression kinetics in cultured MNC. The experiments described above were not informative in terms of defining when Vav function might be most critical for colony development. We postulated that knowing the kinetics of Vav mRNA extinction in response to pulse ODN exposure might be helpful in addressing this question. We therefore determined the effect of Vav ODN exposure on Vav mRNA expression kinetics in normal MNC cultured in suspension and in methylcellulose. To perform these experiments, MNC were first exposed to AS or control sequence ODN for 24 hours in suspension culture, as detailed in the Materials and Methods. After 24
For expression was detectable in a l l of these samples at a l l of the time points sampled.
MNC plated into methylcellulose culturcs aftcr ODN exposure were sampled at days 3. S. and 7 alter initial seeding (Fig 4) . Regardless of the growth factors added. ie. regardless of whether the cultures were designed to support erythroid (Fig 4A) or myeloid (Fig 4B) colony formation. identical results were obtained. In agreement with the results reported above (Fig 2) to either AS or Scr Vav ODN and then cultured in methylcellulose, as described above (Fig 5) . On day 3 or day 7 of culture, cells were washed, suspended in Laemmli buffer, and the lysate corresponding to 2 X I O 5 cells was loaded into each lane. Immunoblotting was then performed as detailed. Figure 5 shows that immunodetectable p95 Vav was greatly diminished at day 3 in cells exposed to the AS ODN when compared with cells exposed to the scrambled (Sc) sequence. This visual impression was confirmed by densitometric scanning, which showed an -75% decrease in the AS band density vs the Scr band density (27 v 102 arbitrary density units, respectively). The identities of the slightly heavier band and the lighter band in the day 3 AS lane are not known, but these could represent an alternatively glycosylated and a degradation product, respectively. It is worth noting that corresponding bands have been observed in Vav immunoprecipitates in the past by ourselves'" and other^.'^ At day 7, when the mRNA kinetic analysis suggests that Vav mRNA levels would be present in the two populations, the immunoblot is also consistent as the protein levels in equal numbers of cells appear equal. The specificity of the antibody is shown on the right side of the figure, where preabsorption of the anti-Vav antibody with a Vav peptide before blotting results in the disappearance of the p95 band."
Vav mRNA expression and malignant progenitor cell cloning efficiency.
Proto-Vav mRNA transcripts have been detected in virtually all leukemic cell lines tested,' but the physiologic significance of such expression remains uncertain. To determine the potential importance of Vav expression in primary malignant hematopoietic cells, peripheral blood or bone marrow MNC were obtained from patients with either AML or CML. Depending on the amount of material available from a given patient, MNC were variably purified (A-, A-T-, CD34') and then tested for the ability of their CFU to form GM colonies after exposure to Vav ODN (Table 2 ). In distinct contrast to results obtained with normal marrow cells, inhibition of GM colony formation was observed in a variable subset of these patients. This proved to be a minority in the small number of AML patient specimens examined ( 1 of 3 patients evaluated). In addition, inhibition of colony growth was modest (-35%).in the 1 patient sample in which this was observed. A much more profound effect was observed in the CML patients, 14 of whom were in chronic phase and 3 in blast crisis. In this population mean inhibition was -80% (P < .001) in comparison to control cultures and was observed in 13 of the 17 cases. Inhibition was also sequence-specific (Table 2 ).
In addition to leukemia patients, we also studied 7 patients with PV. MNC were obtained from peripheral blood, partially purified as above, and then exposed to Vav ODN. Effects on BFU-E colony formation were assessed. Not surprisingly, inhibition was observed in all 7 patients studied. At the highest doses of AS ODN used, there was a mean 2 SD decrease of 81 % 2 4% (P < .OOOl) in comparison to control cultures. This effect was dose-dependent and sequence-specific (Fig 6) . In addition, we concomitantly studied CFU-GM colony formation in 2 of these patients. We observed a mean 2 SD decrease of 76% t 5% in these 2 patients at the highest doses of AS used ( P < . patients, inhibition of colony formation was sequencespecific and dose-dependent (Table 2) .
002). As noted in the CML
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DISCUSSION
In situ studies in developing mouse embryos have shown that Vav is initially expressed at high levels in fetal liver and in blood island^.^,?^ As blood formation spreads to the marrow and spleen, Vav expression becomes detectable, almost exclusively, in these tissues as well as the thymus. At the same time, vav expression is downregulated in liver.35 Furthermore, although Vav is known to be constitutively phosphorylated on serine and tyrosine,lh.'* its level of phos- For personal use only. on October 27, 2017. by guest www.bloodjournal.org From etic cell signal transduction. Surprisingly then, direct functional analyses of Vav's role in hematopoietic cell development have produced contradictory and, to some extent, unexpected r e~u l t s . *~~~'
In support of the concept that Vav is important for blood cell formation, Wulf et al" reported that, when Vav function was perturbed by expressing antisense Vav mRNA transcripts in murine embryonic stem cells, hematopoietic colony forming ability was severely disturbed at a very primitive level. In distinct contrast, Zhang et a1*' and Zmuidzinas et al" have reported that ES cells in which Vav has been "knocked out" by homologous recombination have no apparent defects in forming hematopoietic cells in vitro and can contribute to hematopoietic cell formation in vivo. These results are difficult to reconcile with those of Wulf et al, '5 but suggest that Vav protein may not be required for embryonic hematopoiesis. However, this does not mean that Vav function is inconsequential. Rather, if Vav is missing from embryonic cells at the inception of development, it is possible that its function may be complemented by an alternative protein with similar capabilities. It has been postulated, for example, that NF-E2 knockout mice sustain erythropoiesis in vivo by just such a m e c h a n i~m .~~ Whether the same would be true for Vav, in adult-derived cells in particular, remains unclear. We therefore sought to determine Vav functional requirements in normal and malignant adult human hematopoietic cells by perturbing the gene's expression with AS ODN, the only materials presently available that permit this type of study in adult cells.
Our results lend some support to each of the conflicting reports cited above. In partial agreement with the studies of Wulf et a1," Vav function appears to be quite important for the development of at least one hematopoietic lineage as shown by the marked inhibition of BFU-E-derived colony formation (Fig 2 and Table l) . In contrast to the findings of this group, but in accord with the reports of Zhang et al'" and Zmuidzinas et al," Vav appears to be dispensable for normal myelopoietic cell development ( Table 1) . These results imply that, in normal adult hematopoietic cells, Vav function is most critical during the processes of erythroid lineage commitment and growth. This interpretation is consistent with reports that Vav is phosphorylated in response to KL'.IX and to EP0,38 arguably two of the most critical cytokines that regulate erythropoiesis. Disruption of the signaling pathway stimulated by the receptors for these cytokines might easily result in the generation of an unrecoverable lesiodor erythroid cell development. These findings would also be consistent with previous studies from our group that perturbation of Kit expression in normal adult progenitors with AS ODN also selectively perturbs erythropoiesis."
We cannot yet mechanistically explain why Vav appears to be needed for proliferation of myeloid progenitors derived from myeloproliferative disorders patients, but not from normal individuals. It is easy to posit that signaling mechanisms in malignant cells differ from their normal counterparts or that the putative transcriptional control properties of Vav may also be involved in this phenomenon. Data to support the latter do not exist, but growth factor-mediated changes in Vav phosphorylation in several leukemic cell lines have been
In one such recent report, human leukemic cell lines were exposed to IL-3, GM-CSF. and KL." Effects on Vav were then determined. In several of the lines tested, overall phosphorylation of ~95'"' did not change after exposure to IL-3 and GM-CSF. Nevertheless, there was a measurable increase in ~95""' phosphorylation on tyrosine. In this same study, it was also reported that, when M07e cells were transfected with p210BC"/AH1-, overall phosphorylation of p95"", as well as tyrosine phosphorylation, increased dramatically. Similar findings were noted in p2 1OBcK/""'~-transfected 32Dc 13 cells. These results strongly suggest that Vav may well be activated in the hematopoietic cells of patients with CML, and perhaps in other leukemias as well, in response to myelopoietic growth factors. They would also explain the results we report herein. Why Vav would not be required for proiiferation of normal progenitors is speculative, but presumably relates to the ability of normal myeloid progenitors to complement Vav function if it is perturbed or to preferentially use signaling pathways that do not involve Vav.'"
In attempting to reconcile our results with the conflicting studies on murine embryonic cells discussed above, we considered a number of factors. From a physiologic point of view, it seems reasonable to propose that results obtained in the murine embryonic stem cell system may not necessarily relate to the human system. This would be especially true if one were attempting to compare fetal and adult cells. The literature is replete with examples that show, eg, that cord blood and adult cells behave differently in culture and that these cells may also have different development potentials in vivo as ell.^')^'^ Cell lineage may also be critical because the most recent murine knockout studies suggest that Vav is required for antigen-mediated signaling and lymphoid cell pro"feration.'x~''' Therefore, regardless of which ES cell result is physiologically correct, it follows that neither necessarily predicts how human cells. in particular those derived from an adult, will respond under similar circumstances. Methodologic issues are also important. It is well known that the antisense approach may affect cell functioning in ways that do not relate directly to perturbation of the targeted mRNA.'Z,43 DNNprotein interactions caused by the charge on the DNA backbone used or aptameric effects related to the particular DNA sequence employed are the most commonly cited mechanisms for these artifacts. The system is therefore not as clean as homologous recombination. However, if one is aware of these problems, one can control their experiments to at least minimize, and hopefully avoid altogether, these pitfalls. With this in mind, we have shown that Vav mRNA and protein are absent or greatly diminished only in antisense-treated cells and that during the time that the protein is absent, biologic effects are observed only in one specific lineage. Why our results differ from those obtained using the antisense RNA construct is again speculative, but may relate to the cells examined.
Signaling pathways used by hematopoietic cells are being intensively investigated and are of great interest from both For personal use only. on October 27, 2017. by guest www.bloodjournal.org From the investigational and interventional points of view. However, at the present time, the relative importance of any given protein may be difficult to determine, especially in normal cells, in which expression may be low and numbers available for study are limited. The results presented here suggest that an antisense strategy, if carefully controlled, may be useful in this regard and may also suggest interesting and fruitful areas for future investigation.
